![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro
|
|
|
Reported by Jules Levin
AASLD 2017 Oct 20-24 Wash DC
AASLD: Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B. - (11/01/17)
Jan Martin Berke1, Thierry Verbinnen1, Ying Tan2, Pascale Dehertogh1, Karen Vergauwen1, Koen Vandyck1, Oliver Lenz1;
1Janssen Research & Development, Beerse, Belgium;
2Janssen China Research & Development Center, Shanghai,
China
![1205171](../images/120517/120517-6/1205171.gif)
![1205172](../images/120517/120517-6/1205172.gif)
![1205173](../images/120517/120517-6/1205173.gif)
![1205174](../images/120517/120517-6/1205174.gif)
![1205175](../images/120517/120517-6/1205175.gif)
![1205176](../images/120517/120517-6/1205176.gif)
![1205177](../images/120517/120517-6/1205177.gif)
![1205178](../images/120517/120517-6/1205178.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|